Last updated 9 August 2026 · Originally published 12 April 2021
CBD and CBN sound like siblings. They’re not really, and the difference matters more than the names suggest. One is made by the plant. The other is what’s left when THC gets old.
Where each one comes from
CBD is part of the plant’s normal cannabinoid pathway. In raw hemp much of it begins as CBDA and becomes CBD during heating and processing. Together, CBD and CBDA usually make up the plant’s dominant cannabinoid fraction.
CBN is different. It forms mainly as THC breaks down — exposure to air, heat and time slowly converts one into the other. Older, poorly stored THC-rich cannabis generally contains more CBN, because some of its THC has degraded.
Because fresh cannabis contains very little, commercial CBN is usually made by converting other cannabinoids in a laboratory. That helps explain why it costs considerably more than CBD.
Do either get you high?
Neither will get you high in the way THC does.
CBD is non-intoxicating, full stop. CBN is a little more complicated. It interacts weakly with CB1, the receptor responsible for much of THC’s high. Most oral studies have found little THC-like intoxication, though the 2026 insomnia trial detected modest subjective drug effects at 300 mg.[5]
At ordinary consumer doses, CBN is unlikely to feel anything like THC.
What each is actually used for
CBD has the broader case behind it. Prescription CBD is an approved medicine for certain seizure disorders, and there’s reasonable if inconsistent research on anxiety. Beyond that the evidence thins out quickly — our guide to what the research actually shows goes through it properly.
CBN is sold almost entirely for sleep. That reputation grew from folklore about old cannabis making people drowsy, plus a lab’s marketing claim that was later withdrawn.
For years there was essentially nothing behind it. That has changed. Several controlled human studies have now reported some encouraging results, including fewer night-time awakenings and better self-rated sleep.[3,4] But the findings are inconsistent, and much of the evidence rests on questionnaires rather than objective sleep monitoring.
The strongest laboratory study so far involved just 20 people with diagnosed insomnia. Neither 30 nor 300 mg of CBN improved its main measure — time spent awake during the night. The 300 mg dose did help participants fall asleep faster and improved several secondary measures.[5] That’s enough to make CBN interesting, but nowhere near enough to establish it as a treatment for insomnia. We go through it in CBN and sleep.
One intriguing difference: appetite
In one rat study, CBN increased food intake while CBD reduced it.[2] Same plant, opposite effects.
That’s a single piece of animal research and it hasn’t been confirmed in people. But it’s the sort of finding that makes the minor cannabinoids worth studying separately rather than lumping them together.
Do they work better together?
Possibly, and this is where it gets interesting.
In a rat model of jaw and muscle pain, CBD and CBN each reduced pain on their own — and the combination produced longer-lasting relief than either compound alone.[1] Whether that holds up in humans is unknown.
The complication for consumers is that many CBN products aren’t CBN alone. They may also contain CBD, THC, melatonin or terpenes marketed for sleep. Which means that when a sleep gummy works, there may be no way to tell what did it.
So which should you buy?
Depends what you want, but two things are worth saying plainly.
CBN costs considerably more, and the evidence behind it is far thinner. If you’re paying a premium for CBN specifically, you’re paying for a compound supported by a handful of human trials, with mixed results and very little objective sleep monitoring.
Check what’s actually in it. If a “CBN sleep formula” contains melatonin, you may largely be buying melatonin — which costs a fraction as much. Read the whole ingredients list, not the front of the box.
And if you want to try CBN, look for a batch-specific lab report showing how much is in there. Scarcity creates an incentive to under-dose, and you can’t taste the difference.
The short version
CBD is the plant’s own product, non-intoxicating, with the better-established evidence base and a genuine medical use.
CBN is what THC becomes with age, far less intoxicating than THC, expensive, and sold mainly on a sleep reputation that research has only recently started to examine.
They’re not competitors, and neither replaces the other. They’re different compounds that happen to share a plant — which is true of most of the cannabinoid family, and part of why it’s taken so long to work any of them out.
None of this is medical advice.
For more, see our guides to CBG and CBGA, or browse Cannabinoid Science.
References
- Wong H, Cairns BE. Cannabidiol, cannabinol and their combinations act as peripheral analgesics in a rat model of myofascial pain. Archives of Oral Biology. 2019;104:33–39. doi:10.1016/j.archoralbio.2019.05.028
- Farrimond JA, Whalley BJ, Williams CM. Cannabinol and cannabidiol exert opposing effects on rat feeding patterns. Psychopharmacology. 2012;223(1):117–129. doi:10.1007/s00213-012-2697-x
- Bonn-Miller MO, Feldner MT, Bynion TM, et al. A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality. Experimental and Clinical Psychopharmacology. 2024;32(3):277–284. doi:10.1037/pha0000682
- Kolobaric A, Saleska J, Hewlings SJ, et al. A randomized, double-blind, placebo-controlled trial to assess the effectiveness and safety of melatonin and three formulations of proprietary CBN for improving sleep. Pharmaceuticals. 2024;17(8):977. doi:10.3390/ph17080977
- Lavender I, McCartney D, Marshall N, et al. Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial. Journal of Sleep Research. 2026;e70284. doi:10.1111/jsr.70284
About this article
Updated in August 2026. This update corrects our earlier statement that no research supported CBN as a sleep aid, and adds the human and animal studies published since. With earlier reporting by Petar Petrov.
